Author

Angela Elliott

Observed names: A Elliott, A. Elliott, Elliott, Angela

Observed institutions: University of London, University of Liverpool, University of Dundee, NHS Tayside, London School of Hygiene & Tropical Medicine, MRC University of Glasgow Centre for Virus Research, International Severe Acute Respiratory and Emerging Infection Consortium, Imperial College London, University of Glasgow, University of Edinburgh

OpenAlex ID: A5113929363

Mapping the human genetic architecture of COVID-19

2021 · COVID-19 Host Genetics Initiative, COVID-19 Host Genetics InitiativeLeadership, et al. · Nature · 983

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

2022 · Wanwisa Dejnirattisai, Jiandong Huo, et al. · Cell · 928

PDF

Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study

2021 · Rachael A Evans, Hamish J C McAuley, et al. · The Lancet Respiratory Medicine · 672

Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study

2022 · R A Evans, O C Leavy, et al. · The Lancet Respiratory Medicine · 413

PDF

Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study

2021 · Clark D Russell, Cameron J Fairfield, et al. · The Lancet Microbe · 327

Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19

2021 · Ryan S Thwaites, Ashley Sanchez Sevilla Uruchurtu, et al. · Science Immunology · 235

Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study

2021 · Rishi K Gupta, Ewen M Harrison, et al. · The Lancet Respiratory Medicine · 210

PDF

Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK

2021 · Chloe I Bloom, Thomas M Drake, et al. · The Lancet Respiratory Medicine · 183

PDF

Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study

2021 · Thomas M Drake, Aya M Riad, et al. · The Lancet · 158

PDF

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

2022 · Felicity Liew, Shubha Talwar, et al. · EBioMedicine · 121

Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK

2021 · Annemarie B Docherty, Rachel H Mulholland, et al. · The Lancet Respiratory Medicine · 112

PDF

Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease

2024 · Felicity Liew, Claudia Efstathiou, et al. · Nature Immunology · 107

PDF

Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study

2021 · Michael K Sullivan, Jennifer S Lees, et al. · Nephrology Dialysis Transplantation · 99

PDF

Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study

2021 · Thomas M Drake, Cameron J Fairfield, et al. · The Lancet Rheumatology · 74

PDF

A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus

2018 · Elizabeth R. Allen, Stefanie A. Krumm, et al. · Cell Reports · 62

PDF

Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses

2023 · Benedict D. Michael, Cordelia Dunai, et al. · Nature Communications · 46

PDF

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41

PDF

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39

PDF

International Pediatric COVID-19 Severity Over the Course of the Pandemic

2023 · Yanshan Zhu, Flávia Jacqueline Almeida, et al. · Archives of Pediatrics and Adolescent Medicine · 37

The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection

2023 · Hannah Goldswain, Xiaofeng Dong, et al. · Genome biology · 37

PDF

Importance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England

2021 · Quentin J. Leclerc, Naomi M. Fuller, et al. · BMC Health Services Research · 36

PDF

Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study

2023 · Callum Jackson, Iain D Stewart, et al. · The Lancet Respiratory Medicine · 35

Accelerated immune ageing is associated with COVID-19 disease severity

2024 · Janet M. Lord, Tonny Veenith, et al. · Immunity & Ageing · 34

PDF

Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls

2023 · Bang Zheng, Giulia Vivaldi, et al. · The Lancet Regional Health - Europe · 29

Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study

2023 · Hamish J.C. McAuley, Rachael A. Evans, et al. · EClinicalMedicine · 24

PDF

Works count: 37

Citation count: 5,271

H-index: 25

I10-index: 32